Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood RNA may reveal who responds to heart failure treatment

NCT ID NCT03345446

Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at tiny RNA molecules in the blood of 200 people hospitalized with acute congestive heart failure. Researchers want to see if these RNA levels change as patients receive decongestive therapy and if they can help predict who will respond well to treatment. The goal is to better understand heart failure and find new markers to guide care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2016

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Acute Congestive Heart Failure, either with preserved ejection fraction (HF-pEF) or reduced ejection fraction (HF-rEF). The subjects will be enrolled in the acute CHF setting from two sites: * Beth Israel Deaconess Medical Center (BIDMC; under direction of Dr. Pablo Pinzon-Quintero, Heart Failure/Transplant Attending Physician) * Massachusetts General Hospital (MGH; under direction of Dr. Ravi Shah, Heart Failure/Transplant Attending Physician) Subjects will be drawn from the inpatient population at both hospitals, admitted with a diagnosis of heart failure.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age \>/= 18 years of age 2. Assessment of LV function within the last year or planned during hospital admission 3. Acute CHF diagnosis, requiring clinical signs and/or symptoms (including exertional or rest dyspnea, orthopnea or PND) AND 1. N-terminal pro-BNP level \> 1000 pg/ml or BNP \> 400 pg/ml, OR 2. Clinical evidence of congestion: * X-ray evidence of pulmonary edema or pleural effusions * Elevated JVP, lower extremity edema, or rales on pulmonary examination * Right heart catheterization evidence of elevated filling pressures (RA pressure \> 10 mmHg; PCWP \> 18 mmHg) 4. Clinical response to IV diuretic therapy (as judged by a physician) Exclusion Criteria: 1. Hematocrit at time of consent \< 30% 2. End-stage non-cardiovascular diseases 1. Known HIV/AIDS 2. Cirrhosis 3. Hemodialysis-dependent renal failure 3. Pregnancy (as adjudicated by patient history) 4. Ventricular assist device support 5. Acute mechanical support on admission 6. Post-heart transplant 7. Malignancy within the last 1 year or clinically active rheumatologic or autoimmune illnesses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute congestive heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure diastolic heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute congestive heart failure Heart failure with normal ejection fraction Heart failure with reduced ejection fraction

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.